Antiparkinsonian medication masks motor signal progression in de novo patients

Antiparkinsonian medication masks motor signal progression in de novo patients

<p>Patients not yet receiving medication provide insight to drug-naïve early physiology of Parkinson's Disease (PD). Wearable sensors can measure changes in motor features before and after introduction of antiparkinsonian medication. We aimed to identify features of upper limb br...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Brzezicki, MA, Conway, N, Sotirakis, C, FitzGerald, JJ, Antoniades, CA
Formatua:	Journal article
Hizkuntza:	English
Argitaratua:	Cell Prss 2023

Antzeko izenburuak

Antiparkinsonian medication masks motor signal progression in de novo patients
nork: Maksymilian A. Brzezicki, et al.
Argitaratua: (2023-06-01)

Identification of motor progression in Parkinson's disease using wearable sensors and machine learning
nork: Sotirakis, C, et al.
Argitaratua: (2023)

Predicting future fallers in Parkinson’s disease using kinematic data over a period of 5 years
nork: Sotirakis, C, et al.
Argitaratua: (2024)

Identification of motor progression in Parkinson’s disease using wearable sensors and machine learning
nork: Charalampos Sotirakis, et al.
Argitaratua: (2023-10-01)

Strategy adherence: a specific and rapidly progressive deficit in progressive supranuclear palsy
nork: Brzezicki, MA, et al.
Argitaratua: (2021)

Longitudinal monitoring of progressive supranuclear palsy using body-worn movement sensors
nork: Sotirakis, C, et al.
Argitaratua: (2022)

Predicting future fallers in Parkinson’s disease using kinematic data over a period of 5 years
nork: Charalampos Sotirakis, et al.
Argitaratua: (2024-12-01)

Longitudinal changes of early motor and cognitive symptoms in progressive supranuclear palsy: the OxQUIP study
nork: Pereira, MF, et al.
Argitaratua: (2022)

Discriminating progressive supranuclear palsy from Parkinson's disease using wearable technology and machine learning
nork: De Vos, M, et al.
Argitaratua: (2020)

Oculomotor deficits in Parkinson's disease: Increasing sensitivity using multivariate approaches
nork: Bredemeyer, O, et al.
Argitaratua: (2022)

Amantadine: an antiviral and antiparkinsonian agent
nork: J. Staničová, et al.
Argitaratua: (2001-09-01)

Trends in Antiparkinsonian Medication Use in New Zealand: 1995–2011
nork: T. L. Pitcher, et al.
Argitaratua: (2014-01-01)

Importance of Nanoparticles for the Delivery of Antiparkinsonian Drugs
nork: Sara Silva, et al.
Argitaratua: (2021-04-01)

Drug utilization study of antiparkinsonian medication in Romania during 25 years
nork: Camelia Bucsa, et al.
Argitaratua: (2025-02-01)

Parkinson's disease deficits in time perception to auditory as well as visual stimuli - A large online study
nork: Su, ZH, et al.
Argitaratua: (2022)

Quantifying motor impairment in movement disorders
nork: FitzGerald, J, et al.
Argitaratua: (2018)

Deciphering the actions of antiparkinsonian and antipsychotic drugs on cAMP/DARPP-32 signaling
nork: Gilberto eFisone, et al.
Argitaratua: (2011-07-01)

PHARMACOKINETIC STUDIES OF NEW ANTIPARKINSONIAN DRUG RAPITALAM
nork: Natalya Avdeeva, et al.
Argitaratua: (2016-12-01)

In vitro neuroprotective effects of dua-acting antiparkinsonians
nork: Vera Silva, et al.
Argitaratua: (2022-04-01)

Quantifying Motor Impairment in Movement Disorders
nork: James J. FitzGerald, et al.
Argitaratua: (2018-04-01)

Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication
nork: Carsten Buhmann, et al.
Argitaratua: (2004-02-01)

Efficacy of antiparkinsonian therapy in tremor correction according to tremorography
nork: V. A. Bogacheva, et al.
Argitaratua: (2024-04-01)

Antiparkinsonian Agents in Investigational Polymeric Micro- and Nano-Systems
nork: Nicola Paccione, et al.
Argitaratua: (2022-12-01)

Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder
nork: Caio M. Massari, et al.
Argitaratua: (2017-10-01)

Motor Improvement-Related Regional Cerebral Blood Flow Changes in Parkinson’s Disease in Response to Antiparkinsonian Drugs
nork: Soutarou Taguchi, et al.
Argitaratua: (2019-01-01)

Novel cognitive markers for early diagnosis and monitoring of progressive supranuclear palsy
nork: Brzezicki, M, et al.
Argitaratua: (2021)

Experimental pharmacokinetics of a new antiparkinsonian drug ADK-1113
nork: O. Yu. Kravtsova, et al.
Argitaratua: (2024-06-01)

Disulfide bridge-targeted metabolome mining unravels an antiparkinsonian peptide
nork: Zhiwu Tong, et al.
Argitaratua: (2024-02-01)

Comparison of the antioxidant potential of antiparkinsonian drugs in different in vitro models
nork: Carine Coneglian de Farias, et al.
Argitaratua: (2014-12-01)

Antiparkinsonian effect of dicholine succinate on the model of MPTP-induced parkinsonism
nork: A. K. Sariev, et al.
Argitaratua: (2017-02-01)

Eye movements and deep brain stimulation
nork: FitzGerald, J, et al.
Argitaratua: (2016)

Using saccadometry with deep brain stimulation to study normal and pathological brain function
nork: Antoniades, C, et al.
Argitaratua: (2016)

High resolution photon counting CT permits direct visualisation of directional deep brain stimulation lead segments and markers
nork: Manfield, J, et al.
Argitaratua: (2023)

Antiparkinsonian activity of selective MAO-B inhibitors of different chemical structures
nork: Vladimir N. Fedorov, et al.
Argitaratua: (2024-12-01)

Objectivization of efficiency of antiparkinsonian drug administration in correction of different types of tremor
nork: D. V. Zakharov, et al.
Argitaratua: (2018-07-01)

Antiparkinsonian drugs as potent contributors to nocturnal sleep in patients with Parkinson's disease.
nork: Soutarou Taguchi, et al.
Argitaratua: (2021-01-01)

A novel machine learning based framework for developing composite digital biomarkers of disease progression
nork: Zhai, S, et al.
Argitaratua: (2025)

Development of marked striatal hand with antiparkinsonian medication withdrawal during traditional (Ayurvedic) medicine treatment for Parkinson's disease
nork: Lim, Shen-Yang, et al.
Argitaratua: (2010)

Longitudinal changes of early motor and cognitive symptoms in progressive supranuclear palsy: the OxQUIP study
nork: Marko Bogdanovic, et al.
Argitaratua: (2022-04-01)

Impact of Duration of Parkinsonism and Antiparkinsonian Drugs on Coagulation Parameters in Patients with Parkinson’s Disease
nork: Varun Kodam, et al.
Argitaratua: (2024-10-01)